Merck & Co., Inc. carries a market capitalization of 283.54B, placing it among publicly traded companies globally. Its enterprise value stands at 342.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 283.54B |
| Enterprise Value | 342.23B |
Merck & Co., Inc. currently has 2.47B shares outstanding.
| Shares Outstanding | 2.47B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Merck & Co., Inc. trades at a trailing price-to-earnings ratio of 33.44. The price-to-sales ratio is 4.54, and the price-to-book ratio stands at 4.36.
| PE Ratio | 33.44 |
| PS Ratio | 4.54 |
| PB Ratio | 4.36 |
| P/TBV Ratio | -214.17 |
| P/FCF Ratio | 16.76 |
| P/OCF Ratio | 16.70 |
On an enterprise value basis, Merck & Co., Inc. trades at an EV/EBITDA multiple of 17.81 and an EV/FCF ratio of 17.96. The EV/Sales ratio of 5.20 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.39 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.20 |
| EV / EBITDA | 17.81 |
| EV / EBIT | 26.39 |
| EV / FCF | 17.96 |
Merck & Co., Inc. maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.94, indicating elevated leverage, while an interest coverage ratio of 12.63 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.30 |
| Quick Ratio | 0.66 |
| Debt / Equity | 106.94 |
| Debt / EBITDA | 2.56 |
| Interest Coverage | 12.63 |
Merck & Co., Inc. posts a return on equity of 13.10 and a return on invested capital of 10.64.
| Return on Equity (ROE) | 13.10 |
| Return on Assets (ROA) | 7.33 |
| Return on Invested Capital (ROIC) | 10.64 |
| Return on Capital Employed (ROCE) | 9.17 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.71 |
Over the trailing twelve months, Merck & Co., Inc. has paid 2.70B in income taxes, reflecting an effective tax rate of 23.18.
| Income Tax | 2.70B |
| Effective Tax Rate | 23.18 |
Merck & Co., Inc.'s stock has gained approximately 46.67178% over the past 52 weeks. The 50-day moving average sits at 116.09, while the 200-day moving average is 103.42.
| Beta (5Y) | N/A |
| 52-Week Price Change | 46.67178% |
| 50-Day Moving Average | 116.09 |
| 200-Day Moving Average | 103.42 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Merck & Co., Inc. generated 65.77B in revenue and converted that into 8.94B in net income, yielding earnings per share of 3.58. EBITDA reached 19.22B, while operating income came in at 12.97B.
| Revenue | 65.77B |
| Gross Profit | 48.61B |
| Operating Income | 12.97B |
| Pretax Income | 11.63B |
| Net Income | 8.94B |
| EBITDA | 19.22B |
| EBIT | 12.97B |
| Earnings Per Share (EPS) | 3.58 |
Merck & Co., Inc. holds 5.70B in cash and equivalents against 49.12B in total debt, resulting in a net debt position of 43.79B. Total book value stands at 68.51B, with working capital of 8.07B providing operational flexibility.
| Cash & Cash Equivalents | 5.70B |
| Total Debt | 49.12B |
| Net Debt | 43.79B |
| Equity (Book Value) | 68.51B |
| Book Value Per Share | 27.58 |
| Working Capital | 8.07B |
Merck & Co., Inc. produced 17.89B in operating cash flow over the past twelve months.
| Operating Cash Flow | 17.89B |
| Capital Expenditures | N/A |
| Free Cash Flow | 17.89B |
| FCF Per Share | 7.20 |
Merck & Co., Inc. operates with a gross margin of 73.91, reflecting its pricing power and cost economics. The operating margin of 19.72 and net profit margin of 13.59 provide insight into operational efficiency.
| Gross Margin | 73.91 |
| Operating Margin | 19.72 |
| Pretax Margin | 17.68 |
| Profit Margin | 13.59 |
| EBITDA Margin | 29.23 |
The company's payout ratio of 92.14 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 3.31 |
| Dividend Yield | N/A |
| Payout Ratio | 92.14 |
| Shareholder Yield | -0.29 |
| FCF Yield | 5.97 |
Merck & Co., Inc.'s most recent stock split took place on June 3, 2021 with a 125:131 split ratio.
| Last Split Date | 6/3/2021 |
| Split Ratio | 125:131 |
Merck & Co., Inc. posts an Altman Z-Score of 4.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.77 |